Solid Biosciences Inc. SLDB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -57.4%-2.1pp | -109.9%-15.3pp | -86.8%-21.0pp | -68.2%-17.4pp | -55.3%-9.5pp | |
| Return on assets | -50%-2.9pp | -82.8%-12.2pp | -68.8%-17.2pp | -57.1%-15.5pp | -47.1%-9.4pp | |
| Return on invested capital | -191.5%-65.3pp | -161.1%+1.1pp | -111%-20.5pp | -118.3%-27.5pp | -126.2%-5.3pp | |
| Liquidity | ||||||
| Current ratio | 13.1×+2.2× | 6.1×+0.9× | 6.7×-1.1× | 9.3×-4.1× | 10.9×-4.0× | |
| Quick ratio | 13.1×+2.2× | 6.1×+0.9× | 6.7×-1.1× | 9.3×-4.1× | 10.9×-4.0× | |
| Cash ratio | 9.8×+2.5× | 1.8×-0.9× | 1.7×-1.1× | 4.7×-1.9× | 7.3×-0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.41-23.2% | $2.06-38.8% | $2.31-42.7% | $2.74-41.9% | $4.44-19.6% | |
| Valuation | ||||||
| Market capitalization | $910.66M+145% | $439.41M+175% | $480.45M+78.6% | $376.34M+72.9% | $286.72M-43.0% | |
| Enterprise value | $634.23M+244% | $400.67M+286% | $441.03M+92.3% | $260.46M+77.1% | $99.72M-75.7% | |
| Price / book | 2.4×+1.2× | 2.4×+1.3× | 2.2×+0.6× | 1.5×+0.3× | 1×-1.4× | |
| Free cash flow yield | -19%+9.9pp | -35.8%+27.2pp | -27.7%+6.4pp | -32.8%+6.9pp | -37.4%-19.0pp | |
| Earnings yield | -21.1%+16.6pp | -39.7%+38.4pp | -34.8%+3.3pp | -40.9%+0.7pp | -48.7%-30.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Solid Biosciences Inc.'s ratios come from?
- Every ratio is computed from Solid Biosciences Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
